Zipalertinib plus chemotherapy improves PFS and ORR in REZILIENT-3
Phase 3 REZILIENT 3 reported that zipalertinib plus chemotherapy significantly improved progression-free survival and response rates versus chemotherapy alone in metastatic EGFR exon 20 insertion NSCLC.